Netherlands· NL-b737c624c3c8
ORENCIA 125 mg oplossing voor injectie in een voorgevulde spuit
A abatacept product containing abatacept, registered in Netherlands by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 14 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Abatacept is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AA24 (abatacept), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 9 of them publish a price we can compare per daily dose
Abatacept · ATC L04AA24
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of abatacept costs, country by country.
Normalised to the WHO defined daily dose (27 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Abatacept · price per daily dose (27 mg)
USD · FX 28 Sept 2026
- CH Switzerland$59.45
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- ABATACEPT
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Netherlands (NL)
- ATC code
- L04AA24
- ATC class
- Abatacept
- Defined daily dose
- 27 mg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/07/389
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
63 interactions on record for abatacept.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Abatacept · interactions on record
63 records
- 30 severe
- 26 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Abatacept in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceORENCIA 125 mg, solution injectable en seringue préremplieBRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- IrelandOrencia 125 mg solution for injection in pre-filled penBristol-Myers Squibb Pharma EEIG
- CzechiaORENCIABristol-Myers Squibb Pharma EEIG, Dublin
- FinlandOrenciaBristol-Myers Squibb Pharma EEIG
- BelgiumOrencia 125 mgBristol-Myers Squibb Pharma
- United KingdomOrencia 125mg/1ml solution for injection pre-filled syringesBristol-Myers Squibb Pharmaceuticals Ltd
- IcelandOrenciaBristol-Myers Squibb Pharma EEIG*
- SwedenORENCIA 125 mg Injektionsvätska, lösning i förfylld injektionspennaBristol-Myers Squibb Pharma EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Orencia
- Liechtenstein · Orencia
- Norway · Orencia
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ffb293c8-3068-47d4-8f4c-6a5c0cb2fa2f GET /v1/drugs/ffb293c8-3068-47d4-8f4c-6a5c0cb2fa2f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie",
"route": "Subcutaan gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/orencia-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Abatacept",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp110534",
"excipients": [
"DINATRIUMWATERSTOFFOSFAAT 0-WATER (E 339)",
"NATRIUMDIWATERSTOFFOSFAAT 1-WATER (E 339)",
"POLOXAMEER 188",
"SACCHAROSE",
"STIKSTOF (HEAD SPACE) (E 941)",
"WATER VOOR INJECTIE"
],
"substances": [
"ABATACEPT"
],
"leaflet_url": null,
"authorised_at": "2012/10/04",
"procedure_number": "EMEA/H/C/000701",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/07/389",
"additional_monitoring": "N"
}See everything about abatacept.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.